- Fedasz will Focus on Opening New Markets for Evofem's First
- and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric
acid, and potassium bitartrate)
SAN DIEGO, April 11, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (Nasdaq: EVFM) today
announced the appointment of Karina
Fedasz as its Head of Business Development. At Evofem,
Karina will oversee the company's business development, product and
pipeline portfolios, new business ventures, and the
advancement of access partnerships around the world.
"Evofem is bringing increasing numbers of women access to
Phexxi, a hormone-free contraceptive, in the United States. We are now stepping up
efforts to bring women access to Phexxi outside the U.S.," said
Saundra Pelletier, Chief Executive
Officer of Evofem. "Karina's decades of success in deal-making, in
our ever-increasing global economy, has already started helping
Evofem establish and build the partnerships that will allow Phexxi
access to new markets around the world."
Fedasz has held various executive roles in business development,
operations, finance, and mergers and acquisitions. Earlier in
her career, while at JP Morgan, she executed partnerships and deals
around the globe as well as at a variety of start-ups. These deals
and partnerships have included nine-figure acquisitions and have
assisted companies in growing into multi-million-dollar
corporations in less than three years. Fedasz graduated from
UCLA and received her MBA from Columbia
Business School.
"Evofem offers the opportunity to work with a world-class team
focused on helping women around the globe maintain control of their
reproductive health," said Karina
Fedasz, Head of Business Development. "Our strategy is clear
and set on opening new markets for Phexxi outside the U.S."
Evofem will report its first-quarter 2022 results on
May 4, 2022.
About Phexxi® (lactic acid, citric acid, and
potassium bitartrate)
Phexxi® is an on-demand method of birth control used to prevent
pregnancy. Phexxi is not effective when used after sex.
Important Safety Information
- Rare cases (0.36%) of bladder and kidney infections have been
reported. If you have a history of urinary tract problems that keep
coming back, you should not use Phexxi.
- Contact your healthcare provider if you are experiencing
genitourinary side effects such as vaginal burning, itching,
discharge, genital discomfort (including in male partners), yeast
infection, urinary tract infection, or bacterial vaginosis.
- Phexxi does not protect against sexually transmitted
infections, including HIV.
For more information about Phexxi, talk to your healthcare
provider and see full Product Information
at www.phexxi.com.
Please report side effects by contacting Evofem Biosciences
toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
Intended for United States residents only.
About Evofem Biosciences
Evofem Biosciences, Inc. (Nasdaq: EVFM) is developing and
commercializing innovative products to address unmet needs in
women's sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from chlamydia and
gonorrhea. The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of sex.
Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Forward-Looking Statements
This press release includes "forward-looking statements" within the
meaning of the safe harbor for forward-looking statements provided
by Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. Various
factors could cause actual results to differ materially from those
discussed or implied in the forward-looking statements, including,
without limitation, market and other conditions, the likelihood or
ability to consummate an ex-U.S. transaction, whether any
regulatory approvals for marketing of Phexxi outside the U.S. can
be obtained, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Important factors that
could cause actual results to differ materially from those
discussed or implied in the forward-looking statements or that
could impair the value of Evofem Biosciences' assets and business
are disclosed in the Company's SEC filings, including its Annual
Report on Form 10-K for the year ended December 31, 2021,
filed with the SEC on March 10, 2022. All forward-looking
statements are expressly qualified in their entirety by such
factors. The Company does not undertake any duty to update any
forward-looking statement except as required by law.
Media Contact
Jack Hirschfield
Evofem Biosciences, Inc.
jhirschfield@evofem.com
(512) 674-5163
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-announces-karina-fedasz-as-companys-new-head-of-business-development-301522412.html
SOURCE Evofem Biosciences, Inc.